Testing effectiveness (Phase 2)Ended earlyNCT04004065
What this trial is testing
Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
Who this might be right for
Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc. 62